Search

Displaying results 181 - 190 of 450 in total
  1. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    [L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800]

  2. Drug

    MX006

    go.drugbank.com/drugs/DB33934
    Experimental

    MX006 is under investigation in clinical trial NCT07807241 (A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3).

  3. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    Anileridine is a synthetic opioid and strong analgesic medication. It is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effe...

  4. Drug

    Sepetaprost

    go.drugbank.com/drugs/DB12043
    Investigational

    Sepetaprost has been used in trials studying the treatment of Open Angle-glaucoma, Ocular Hypertension, and Mild Open Angle-glaucoma (OAG).

  5. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRĪ±), covalently joined by a cleavable disulfide linker to the genotoxic compound D...

  6. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.

  7. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718]

  8. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. It results from a gain-of-function missense mutation in FGFR3 that results in a dramatic suppression of bone growth, both in volume ...

  9. Drug

    Pentobarbital

    go.drugbank.com/drugs/DB00312
    ApprovedVet approved

    A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may ...

  10. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.